The effect of aspartate β-hydroxylase inhibition on cancer immunotherapy

abstract in e-form
Creative Commons License IconCreative Commons BY Icon
Thumbnail
File can be accessed.Get publication
Author
Johari, Shweta Dilip
Krausová, Kateřina
Žucha, Barbora
Madureira Trufen, Carlos Eduardo
Poláková, IngridORCiD Profile - 0000-0003-1315-0924WoS Profile - I-9355-2014Scopus Profile - 24766742200
Olsen, Mark
Šmahel, MichalORCiD Profile - 0000-0002-0366-4932WoS Profile - H-4317-2017Scopus Profile - 6701604039
CCL-CONFERENCE CZECHOSLOVAKIA LTD.

Publication date
2024
Published in
Neuveden
Metadata
Show full item record
Collections
Abstract
Aspartate β-hydroxylase (ASPH) is overexpressed in 70-90% of various solid tumors, contributing to tumor cell proliferation, migration, and invasion. In addition, recombinant ASPH inhibits natural killer (NK) cells, but an effect on other immune cells has not been described. Small molecule inhibitors have been developed to target tumors overexpressing ASPH. In this study, we combined ASPH inhibition with immunotherapy to enhance cancer therapy and seek out affected immune cells.
Keywords
aspartate β-hydroxylase, immunotherapy, ASPH inhibitor, Elispot assay
Permanent link
https://hdl.handle.net/20.500.14178/2644
License

Full text of this result is licensed under: Creative Commons Uveďte původ 4.0 International

Show license terms